|
1
|
Rebello RJ, Oing C, Knudsen KE, Loeb S,
Johnson DC, Reiter RE, Gillessen S, Van der Kwast T and Bristow RG:
Prostate cancer. Nat Rev Dis Primers. 7:92021. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Sekhoacha M, Riet K, Motloung P, Gumenku
L, Adegoke A and Mashele S: Prostate cancer review: Genetics,
diagnosis, treatment options, and alternative approaches.
Molecules. 27:57302022. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Sun D, Li H, Cao M, He S, Lei L, Peng J
and Chen W: Cancer burden in China: Trends, risk factors and
prevention. Cancer Biol Med. 17:879–895. 2020. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Qiu H, Cao S and Xu R: Cancer incidence,
mortality, and burden in China: A time-trend analysis and
comparison with the United States and United Kingdom based on the
global epidemiological data released in 2020. Cancer Commun (Lond).
41:1037–1048. 2021. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Williams IS, McVey A, Perera S, O'Brien
JS, Kostos L, Chen K, Siva S, Azad AA, Murphy DG, Kasivisvanathan
V, et al: Modern paradigms for prostate cancer detection and
management. Med J Aust. 217:424–433. 2022. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Mottet N, van den Bergh RCN, Briers E, Van
den Broeck T, Cumberbatch MG, De Santis M, Fanti S, Fossati N,
Gandaglia G, Gillessen S, et al: EAU-EANM-ESTRO-ESUR-SIOG
guidelines on prostate cancer-2020 update. Part 1: Screening,
diagnosis, and local treatment with curative intent. Eur Urol.
79:243–262. 2021. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Desai K, McManus JM and Sharifi N:
Hormonal therapy for prostate cancer. Endocr Rev. 42:354–373. 2021.
View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Crawford ED, Heidenreich A, Lawrentschuk
N, Tombal B, Pompeo ACL, Mendoza-Valdes A, Miller K, Debruyne FMJ
and Klotz L: Androgen-targeted therapy in men with prostate cancer:
Evolving practice and future considerations. Prostate Cancer
Prostatic Dis. 22:24–38. 2019. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Zhu Y, Mo M, Wei Y, Wu J, Pan J, Freedland
SJ, Zheng Y and Ye D: Epidemiology and genomics of prostate cancer
in Asian men. Nat Rev Urol. 18:282–301. 2021. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Iwamoto H, Izumi K, Makino T and Mizokami
A: Androgen deprivation therapy in high-risk localized and locally
advanced prostate cancer. Cancers (Basel). 14:18032022. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Yu EM and Aragon-Ching JB: Advances with
androgen deprivation therapy for prostate cancer. Expert Opin
Pharmacother. 23:1015–1033. 2022. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Merseburger AS, Hammerer P, Rozet F,
Roumeguère T, Caffo O, da Silva FC and Alcaraz A: Androgen
deprivation therapy in castrate-resistant prostate cancer: How
important is GnRH agonist backbone therapy? World J Urol.
33:1079–1085. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Raja T, Sud R, Addla S, Sarkar KK, Sridhar
PS, Talreja V, Jain M and Patil K: Gonadotropin-releasing hormone
agonists in prostate cancer: A comparative review of efficacy and
safety. Indian J Cancer. 59:S142–S159. 2022. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Persad R: Leuprorelin: A leading role in
advanced prostate cancer therapy. Hosp Med. 64:360–363. 2003.
View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Wilson AC, Meethal SV, Bowen RL and Atwood
CS: Leuprolide acetate: A drug of diverse clinical applications.
Expert Opin Investig Drugs. 16:1851–1863. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Shim M, Bang WJ, Oh CY, Lee YS and Cho JS:
Effectiveness of three different luteinizing hormone-releasing
hormone agonists in the chemical castration of patients with
prostate cancer: Goserelin versus triptorelin versus leuprolide.
Investig Clin Urol. 60:244–250. 2019. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
McKay RR, Xie W, Ye H, Fennessy FM, Zhang
Z, Lis R, Calagua C, Rathkopf D, Laudone VP, Bubley GJ, et al:
Results of a randomized phase II trial of intense androgen
deprivation therapy prior to radical prostatectomy in men with
high-risk localized prostate cancer. J Urol. 206:80–87. 2021.
View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Mizokami A, Ueno S, Fukagai T, Ito K,
Ehara H, Kinbara H, Origasa H, Usami M, Namiki M and Akaza H:
Global update on defining and treating high-risk localized prostate
cancer with leuprorelin: An Asian perspective. BJU Int. 99 (Suppl
1):S6–S9; discussion 17–18. 2007. View Article : Google Scholar
|
|
19
|
Suzuki K, Namiki M, Fujimoto T,
Takabayashi N, Kudou K and Akaza H: Efficacy and safety of
leuprorelin acetate 6-month depot in prostate cancer patients: A
phase III, randomized, open-label, parallel-group, comparative
study in Japan. Jpn J Clin Oncol. 45:1168–1174. 2015.PubMed/NCBI
|
|
20
|
Chung BH, Horie S and Chiong E: Clinical
studies investigating the use of leuprorelin for prostate cancer in
Asia. Prostate Int. 8:1–9. 2020. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Li WL, Shi QB, Han WH and Li CM: Influence
on efficacy and immune function in patients with prostate cancer by
using intensity-modulated radiotherapy combined with endocrine
therapy. Pract J Cancer. 34:1275–1279. 2019.(In Chinese).
|
|
22
|
Su JQ, Xin JH, Zhao XR and Guan MG: The
effect of intensity-modulated radiotherapy combined with endocrine
therapy on prostate cancer. Guide Chin Med. 5:110–112. 2022.(In
Chinese).
|
|
23
|
Ling KN, Yang JR, Li BJ, Li J, Ji ZQ and
Liu JZ: A study on the clinical efficacy of medical castration in
treatment of prostate cancer complicated with urinary retention.
Chin J Clin Med. 15:340–344. 2022.(In Chinese).
|
|
24
|
Mohler JL, Armstrong AJ, Bahnson RR,
D'Amico AV, Davis BJ, Eastham JA, Enke CA, Farrington TA, Higano
CS, Horwitz EM, et al: Prostate cancer, version 1.2016. J Natl
Compr Canc Netw. 14:19–30. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Epstein JI, Egevad L, Amin MB, Delahunt B,
Srigley JR and Humphrey PA; Grading Committee, : The 2014
international society of urological pathology (ISUP) consensus
conference on gleason grading of prostatic carcinoma: Definition of
grading patterns and proposal for a new grading system. Am J Surg
Pathol. 40:244–252. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Wu LX, Lei L, Zhu YC, Du KQ, Li XF, Chen
HF, Wang WX and Xu CW: A prostate cancer patient with isolated lung
metastases: A case report. Transl Cancer Res. 9:2064–2068. 2020.
View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Zhang L, Tao D and Wang S: Clinical
evaluation of enantone in the treatment of prostate cancer.
Zhonghua Zhong Liu Za Zhi. 19:218–220. 1997.(In Chinese).
PubMed/NCBI
|
|
28
|
Padula GD, Zelefsky MJ, Venkatraman ES,
Fuks Z, Lee HJ, Natale L and Leibel SA: Normalization of serum
testosterone levels in patients treated with neoadjuvant hormonal
therapy and three-dimensional conformal radiotherapy for prostate
cancer. Int J Radiat Oncol Biol Phys. 52:439–443. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Marberger M, Kaisary AV, Shore ND, Karlin
GS, Savulsky C, Mis R, Leuratti C and Germa JR: Effectiveness,
pharmacokinetics, and safety of a new sustained-release leuprolide
acetate 3.75-mg depot formulation for testosterone suppression in
patients with prostate cancer: A phase III, open-label,
international multicenter study. Clin Ther. 32:744–757. 2010.
View Article : Google Scholar : PubMed/NCBI
|
|
30
|
George DJ, Saad F, Cookson MS, Saltzstein
DR, Tutrone R, Bossi A, Brown B, Selby B, Lu S, Buckley D, et al:
Impact of concomitant prostate cancer medications on efficacy and
safety of relugolix versus leuprolide in men with advanced prostate
cancer. Clin Genitourin Cancer. 21:383–392. e22023. View Article : Google Scholar : PubMed/NCBI
|
|
31
|
LBA02-09 EMBARK, . A Phase 3 randomized
study of enzalutamide or placebo plus leuprolide acetate and
enzalutamide monotherapy in high-risk biochemically recurrent
prostate cancer. J Urol. 210:224–226. 2023. View Article : Google Scholar
|
